Leona

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Retrieved on: 
Thursday, September 21, 2023
Leona, HSCS, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital (Manhattan), Cardiovascular disease, ECG, Intelligence, Research, Doctor of Philosophy, Assistant, Annals of Pediatric Cardiology, Cardiac electrophysiology, Science, Patent, Patient, Division, Mount Sinai Hospital, Algorithm, Machine learning, Cardiology, Diagnosis, Policy, MPH, Mount Sinai Health System, Death, D3M, Medical device, Management, Pharmaceutical industry, MD, Medicine

HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.

Key Points: 
  • HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.
  • HeartSciences and Icahn Mount Sinai have also entered into a memorandum of understanding for ongoing cooperation encompassing de-identified data access, on-going research, and the evaluation of HeartSciences’ MyoVista® wavECGTM.
  • Mount Sinai and Mount Sinai faculty, including Dr. Nadkarni; Dr. Vaid; Joshua Lampert, MD, Medical Director of Machine Learning for Mount Sinai Heart; Vivek Reddy, MD, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn Mount Sinai; and Son Duong, MD, Assistant Professor of Pediatrics (Pediatric Cardiology) at Icahn Mount Sinai, have a financial interest in this technology and in HeartSciences.
  • The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.

CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Leona, EASL, Conference call, PBC, CMC, ULN, ALP, Research, Alkaline phosphatase, European Association for the Study of the Liver, Fibrosis, Primary biliary cholangitis, Hypoglycemia, HIV disease progression rates, Patient, Investment, Risk, Itch, GPR119, UDCA, Therapy, Hand, Technology transfer, Disease, Pharmaceutical industry, Cryptocurrency, Liver, Conference

NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET
    NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second quarter ended June 30, 2023.
  • Research and development expenses for the three months ended June 30, 2023, and 2022 were $19.5 million and $17.9 million, respectively.
  • Research and development expenses for the six months ended June 30, 2023 were $38.1 million and $36.3 million, respectively.
  • Net loss for the six months ended June 30, 2023 was $29.6 million and $54.9 million, or ($0.30) and ($0.62), respectively.

Registration Now Open for American Diabetes Association 2023 Summer Camps

Retrieved on: 
Thursday, May 18, 2023
Leona, Volunteering, Learning, Diabetes, Social skills, Anger, Loneliness, Sadness, Eli Lilly, Glucose meter, Child, American Diabetes Association, Novo Nordisk, Himawari (satellites), Health, ADA, Environment, Inhalable insulin, Mental health, Nursing, Pharmaceutical industry

ARLINGTON, Va., May 18, 2023 /PRNewswire/ -- Registration is open for the American Diabetes Association® (ADA) 2023 summer camp season. The ADA runs 33 camps located in 20 states throughout the summer season, June through August. ADA camps provide a medically safe environment where children with diabetes and their families can partake in a fun-filled summer camp experience while learning how to better manage diabetes. ADA camps also serve as a connecting point for children to develop lifelong friendships that help improve their social skills, self-confidence, and independence.

Key Points: 
  • ARLINGTON, Va., May 18, 2023 /PRNewswire/ -- Registration is open for the American Diabetes Association® (ADA) 2023 summer camp season.
  • ADA camps provide a medically safe environment where children with diabetes and their families can partake in a fun-filled summer camp experience while learning how to better manage diabetes.
  • "ADA camps provide the support families need to understand how to manage and live well with diabetes.
  • Registration is also now open for the ADA 2023 fall camp and family retreat programs in Hawaii, Tennessee, Texas, and Washington.

Interim Results of Study That Used Non-invasive Wireless Patches to Monitor Myoelectric Activity of Crohn’s Disease Patients in Flare and Remission

Retrieved on: 
Tuesday, May 9, 2023
Leona, Medicine, Stanford University, IBD, Proportional myoelectric control, SanDisk Professional, Innovation, Biomarker, Endoscopy, WPS, Stomach, Colon, Defecation, AGA, Digital health, Patient, Physician, IBS, Hepatology, Annual general meeting, Poster, FDA, Medical device, Medical imaging, Gastroenterology

Wireless Patches Reveal Differences in Colonic Motility Between Acute Crohn’s Disease Patients and Healthy Controls demonstrated findings from a study conducted by researchers at Stanford University in collaboration with G-Tech.

Key Points: 
  • Wireless Patches Reveal Differences in Colonic Motility Between Acute Crohn’s Disease Patients and Healthy Controls demonstrated findings from a study conducted by researchers at Stanford University in collaboration with G-Tech.
  • In the study, 66 Crohn’s Disease patients and 38 healthy controls wore three abdominal patches for three to six consecutive days while pursuing regular daily activities.
  • Results from the study show distinguishing characteristics between patients in an acute flare condition as determined by their physician, and healthy controls.
  • Compared to healthy controls, the reduced colon activity in Crohn’s Disease patients becomes more statistically significant as the severity score increases.

First Look at Data on Biosense Webster's Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023

Retrieved on: 
Saturday, February 4, 2023
PFA, Data monitoring committee, Paroxysmal attack, PVI, President of the European Union, Trial of the century, Atrial fibrillation, Pulmonary vein stenosis, Vein, PF, Safety, Leona, Johnson & Johnson, Patient, Icahn School of Medicine at Mount Sinai, Mount, Clinical trial, Recurrence, Kansas Day, Reflex, Risk, Medical Affairs Bureau, Cardiac electrophysiology, Arrhythmia, IRE, Catheter, I-40, Mount Sinai Health System, Mount Sinai Hospital (Manhattan), MD, Medical imaging, Medical device, Pharmaceutical industry, Ventricular fibrillation, Medicine, Electrophysiology

IRVINE, Calif., Feb. 3, 2023 /PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced that positive results from the inspIRE company-sponsored clinical trial were presented as a late breaker, titled "Paroxysmal AF Ablation Using a Variable-Loop Pulsed Field Ablation Catheter Integrated with a 3D Mapping System: One-Year Outcomes from inspIRE," at the 28th Annual International AF Symposium.

Key Points: 
  • In addition to being presented as an AF Symposium late breaker, the data will be simultaneously published in Circulation: Arrhythmia and Electrophysiology.
  • Pulsed Field Ablation (PFA) represents a new approach to treating atrial fibrillation (AFib), utilizing a controlled electric field to ablate cardiac tissue through a process called irreversible electroporation (IRE).
  • In wave II, an independent Data Monitoring Committee declared early success after 186-patient enrollment and 60 patients completing 12-month follow-up.
  • VARIPULSE™ is a steerable, multielectrode, catheter enabling cardiac electrophysiological mapping and ablation functionalities through the investigational TRUPULSE™ Generator.

BEYOND TYPE 1 AND NICK JONAS LAUNCH #SeeTheSigns CAMPAIGN FOR WORLD DIABETES DAY 11/14

Retrieved on: 
Monday, November 14, 2022
People, SAN, Beyond, Urination, Awareness, Diabetic ketoacidosis, Volunteering, Weight loss, Leona, Diabetes, World Diabetes Day, Program, Death, CEO, Finger, T1D, Life, DKA, Degenerative disease, Pharmaceutical industry

SAN MATEO, Calif., Nov. 14, 2022 /PRNewswire/ -- Today is World Diabetes Day and Beyond Type 1, a global non-profit dedicated to the diabetes community, launches #SeeTheSigns, a campaign from the diabetes community to raise awareness about the signs of diabetes by sharing their personal stories.

Key Points: 
  • SAN MATEO, Calif., Nov. 14, 2022 /PRNewswire/ -- Today is World Diabetes Day and Beyond Type 1 , a global non-profit dedicated to the diabetes community, launches #SeeTheSigns, a campaign from the diabetes community to raise awareness about the signs of diabetes by sharing their personal stories.
  • Nick Jonas and the diabetes community are encouraging everyone to #SeeTheSigns of diabetes by sharing personal stories.
  • Nick Jonas, the multi-platinum recording artist, actor and Beyond Type 1's co-founder, kickstarted the campaign on Instagram to over 33 million followers, sharing that he had four signs.
  • Jonas was diagnosed with type 1 diabetes (T1D) at 13 years old and will celebrate his "diaversary" on Nov. 15, one day after World Diabetes Day.

JDRF Announces Launch of global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Time, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, CDN, Insulin, Industry, Diabetes, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, The Lancet, International Society, Diagnosis, IDF, Heart, Research, GLOBE, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Management, Medical device, Child, Index, Facebook, Instagram, T1D, Lilly

TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).

Key Points: 
  • TORONTO and NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).
  • The T1D Index and accompanying research has been published in the world leading diabetes and endocrinology medical journal, The Lancet Diabetes & Endocrinology.
  • This is why I am so proud that significant progress has been made to understand T1Ds global impact through the T1D Index.
  • It is a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, Multimedia, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, View, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

JDRF Announces Launch of Global Type 1 Diabetes Index

Retrieved on: 
Wednesday, September 21, 2022
Leona, International Diabetes Federation, Disability, Volunteering, Incidence, Efficiency, Diet, Twitter, Risk, Prevalence, Publication, NEW, Insulin, Industry, Abbott, Endocrinology, Pancreas, Government, Mental health, Vertex Pharmaceuticals, American Association of Clinical Endocrinologists, JDRF, Technology, Quality of life, Public health, Life, CGMS-A, International Society, Diagnosis, IDF, Heart, Research, Awareness, The Leona M. and Harry B. Helmsley Charitable Trust, Education, ISPAD, International Society for Pediatric and Adolescent Diabetes, Death, Pump, Pharmaceutical industry, Medical device, Seaweed, Child, Index, Facebook, Instagram, T1D, Lilly

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the T1D crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of T1D. Leveraging data and insights from the T1D Index can help change the lives of people living with T1D by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.

Key Points: 
  • The first-of-its-kind index will raise awareness of the burden and unmet need of people living with type 1 diabetes around the world.
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announcesthe launch of the Type 1 Diabetes Index (T1D Index).The T1D Index is afirst-of-its-kind data simulationtool that measures the human and public health impact of the T1D crisis in every country across the globe.
  • The T1DIndex and accompanying research has been published in the leading diabetes and endocrinology medical journal, The Lancet Diabetes &Endocrinology.
  • Itis a collaborative development by JDRF, Life for a Child , International Society for Pediatric and Adolescent Diabetes (ISPAD) , International Diabetes Federation (IDF), and Beyond Type 1 .

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022
U.S. Securities and Exchange Commission, Leona, Association, Hand, Survival, Primary biliary cholangitis, NDA, CEO, EASL, PBC, Investment, Alkaline phosphatase, Clinical trial, Conference call, Disease, European Medicines Agency, Annual report, Thakeham, Security (finance), Priority, Fibrosis, Patient, Liver disease, Therapy, American Association for the Study of Liver Diseases, Twitter, Hypoglycemia, Itch, Associate, Safety, Doctor of Philosophy, NASDAQ, GPR119, Research, Hepatitis, Food and Drug Administration, University, Investor, Ursodeoxycholic acid, European Association for the Study of the Liver, University of Toronto, LinkedIn, Pharmaceutical industry, Dentistry, GLOBE, Liver, Conference

NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • ET
    NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second quarter ended June 30, 2022.
  • Second Quarter and Six Months Ended June 30, 2022, Financial Results
    Research and development expenses for the three months ended June 30, 2022, and 2021 were $17.9 million and $16.7 million, respectively.
  • Research and development expenses for the six months ended June 30, 2022, and 2021 were $36.3 million and $29.1 million, respectively.
  • General and administrative expenses for the six months ended June 30, 2022, and 2021 were $12.0 million and $11.8 million, respectively.